Table 2 Patients characteristics
From: Feasibility of constant dose rate VMAT in the treatment of nasopharyngeal cancer patients
Patients no. | Staging | Gender | Age | PTC-CTV volume (cm3) | PTV-GTV volume (cm3) |
|---|---|---|---|---|---|
1 | T2N2MX | M | 48 | 618.0 | 59.6 |
2 | T2N1MX | M | 63 | 757.7 | 85.5 |
3 | T3N0M0 | M | 71 | 589.1 | 62.2 |
4 | T4N0MX | M | 59 | 546.8 | 171.0 |
5 | T3N3MX | M | 71 | 504.2 | 92.4 |
6 | T2N2MX | F | 66 | 416.5 | 64.4 |
7 | T4N0MX | M | 55 | 739.7 | 83.4 |
8 | T2N2MX | M | 39 | 498.1 | 45.3 |
9 | T2N3MX | M | 48 | 462.4 | 45.8 |
10 | T1N1M0 | M | 62 | 603.8 | 93.1 |
11 | T2bN1M0 | F | 55 | 725.6 | 89.7 |
12 | T2bN2M0 | F | 65 | 668.0 | 92.8 |